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Background
We are conducting a Phase II clinical trial of the HER2
peptide vaccine AE37+GM-CSF for prevention of breast
cancer recurrence in disease-free, node-positive or high-
risk node-negative patients, who have completed stan-
dard of care therapy. AE37, an Ii-Key hybrid of the
HER2/neu derived peptide AE36 (aa:776-790), is an
MHC Class II epitope capable of stimulating CD4+
helper T cells. Here, we examine the relationship
between HER2 antibody response (AR) and clinical
recurrence (CR).
Methods
Patients with any level of HER2 expression (IHC1-3+)
were randomized to receive six monthly intradermal
inoculations of AE37+GM-CSF or GM-CSF alone (con-
trols) during the primary vaccination series (PVS) then
four booster vaccinations administered every six months.
Prior to vaccination (R0) and after the PVS (R6), serum
samples were tested for AR against 178 overlapping 17-
mer peptides spanning the entire HER2 protein mole-
cule. Using flow cytometry, the percentage of anti-HER2
specific antibodies was measured and expressed as mean
fluorescent intensity (MFI). Sub group analysis was
completed on HER2 over-expressers (OE) (IHC3+) ver-
sus non over-expressers (nOE) (IHC1-2+) and hormone
receptor positive (HR+) (ER or PR+) versus HR-
patients. Data are means and compared using a chi-
square and students t test as appropriate.
Results
Of 298 enrolled patients, 153 were vaccinated while 145
were randomized to the control arm. Ten nonrecurrent
(NR) and five recurrent (R) vaccinated patients were
selected and matched for clinico-pathologic factors.
HER2 AR was less in NR versus R at R0 (3659mfi ± 70 vs
4799mfi ± 170, p < 0.01) and R6 (3832mfi ± 82 vs
4832mfi ± 30, p < 0.01). ΔR6 (R6-R0), AR change post-
PVS, was increased in NR compared to R patients
(174mfi ± 36 vs 33mfi ± 70, p < 0.07). AR was greater in
HER2 OE compared to nOE (R0: 4991mfi ± 169 vs
3563mfi ± 70, R6: 4721mfi ± 127 vs 3888mfi ± 84, p <
0.01). nOE exhibited larger ΔR6 HER2 AR (325mfi ± 36
vs -269.96mfi ± 69, p < 0.01). AR was greater in HR+
compared to HR- at R0 (4214mfi ± 91 vs 3336mfi ± 62,
p < 0.01) and R6 (4448mfi ± 86 vs 3037mfi ± 54, p <
0.01) with HR+ patients exhibiting larger ΔR6 HER2 AR
(233mfi ± 40 vs -299mfi ± 36, p < 0.01).
Conclusions
In a prospective Phase II trial of a CD4+ -eliciting HER2
peptide vaccine, AE37+GM-CSF, patients who recur
have higher levels of pre-existing antibodies and lower
levels of antibody induction. This suggests that induc-
tion, not amplification, of an immune response may be
important. Significantly higher AR change post-vaccina-
tion in HER2 nOE and HR+ patients suggests benefit of
vaccination in less aggressive disease.
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